Infants and proton pump inhibitors: Tribulations, no trials

Journal of Pediatric Gastroenterology and Nutrition

Volumn 45, Issue 4, 2007, Pages 395-398

  Orenstein, Susan R ^a   Hassall, Eric ^b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

OMEPRAZOLE; PLACEBO; PROTON PUMP INHIBITOR;

CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COMORBIDITY; DRUG FORMULARY; EDITORIAL; ESOPHAGITIS; GASTROESOPHAGEAL REFLUX; HEALTH CARE PLANNING; HUMAN; INFANT; PREMATURITY; PRESCRIPTION; PRIORITY JOURNAL; STOMACH PH; TREATMENT DURATION;

ANTI-ULCER AGENTS; DRUG UTILIZATION REVIEW; GASTROESOPHAGEAL REFLUX; HUMANS; INFANT; PROTON PUMP INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH SUBJECTS;

EID: 37349075423     PISSN: 02772116     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPG.0b013e31812e011d     Document Type: Editorial

References (29)

1. Barron JJ, Tan H, Spalding J, et al. Proton pump inhibitor utilization patterns in infants. J Pediatr Gastroenterol Nutr 2007;45:421-427.
2. Foroutan HR, Ghafari M. Gastroesophageal reflux as cause of chronic respiratory symptoms. Indian J Pediatr 2002;69:137-9.
3. Ay M, Sivasli E, Bayraktaroglu Z, et al. Association of asthma with gastroesophageal reflux disease in children. J Chin Med Assoc 2004;67:63-6.
4. Ciftci E, Gunes M, Koksal Y, et al. Underlying causes of recurrent pneumonia in Turkish children in a university hospital. J Trop Pediatr 2003;49:212-5.
5. Yuksel H, Yilmaz O, Kirmaz C, et al. Frequency of gastroesophageal reflux disease in nonatopic children with asthma-like airway disease. Respir Med 2006;100:393-8.
6. Colletti RB, Hassall E, Heyman MB, et al. Use of proton pump inhibitors (PPIs) by pediatric gastroenterologists [abstract]. J Pediatr Gastroenterol Nutr 2001;33:414.
7. Hassall E. Mistaking "life" (as we know it) for "disease". Am J Gastroenterol 2006;101:2434-6.
8. Moore DJ, Tao BS, Lines DR, et al. Double-blind placebo-controlled trial of omeprazole in irritable infants with gastroesophageal reflux. J Pediatr 2003;143:219-23.
9. Omari TI, Haslam RR, Lundborg P, et al. Effect of omeprazole on acid gastroesophageal reflux and gastric acidity in preterm infants with pathological acid reflux. J Pediatr Gastroenterol Nutr 2007;44:41-4.
10. Orenstein SR, Shalaby TM, Kelsey SF, et al. Natural history of infant reflux esophagitis: symptoms and morphometric histology during one year without pharmacotherapy. Am J Gastroenterol 2006;101:628-40.
11. Kleinman L, Rothman M, Strauss R, et al. The infant gastroesophageal reflux questionnaire revised: development and validation as an evaluative instrument. Clin Gastroenterol Hepatol 2006;4:588-96.
12. Kleinman L, Revicki DA, Flood E. Validation issues in questionnaires for diagnosis and monitoring of gastroesophageal reflux disease in children. Curr Gastroenterol Rep 2006;8:230-6.
13. Orenstein SR, Shalaby TM, Devandry SN, et al. Famotidine for infant gastro-oesophageal reflux: a multi-centre, randomized, placebo-controlled, withdrawal trial. Aliment Pharmacol Ther 2003;17:1097-107.
14. Gillen D, Wirz AA, Ardill JE, et al. Rebound hypersecretion after omeprazole and its relation to on-treatment acid suppression and Helicobacter pylori status. Gastroenterology 1999;116:239-47.
15. Fossmark R, Johnsen G, Johanessen E, et al. Rebound acid hypersecretion after long-term inhibition of gastric acid secretion. Aliment Pharmacol Ther 2005;21:149-54.
16. Sandvik AK, Brenna E, Waldum HL. Review article: the pharmacological inhibition of gastric acid secretion-tolerance and rebound. Aliment Pharmacol Ther 1997;11:1013-8.
17. Orenstein SR. Infantile reflux: different from adult reflux. Am J Med 1997;103:114S-9S.
18. Rudolph CD, Mazur LJ, Liptak GS, et al. Guidelines for evaluation and treatment of gastroesophageal reflux in infants and children: recommendations of the North American Society for Pediatric Gastroenterology and Nutrition. J Pediatr Gastroenterol Nutr 2001;32 (Suppl 2):S1-31.
19. Barr RG. Excessive crying. In: Sameroff AJ, Lewis M, Miller SM (eds). Handbook of Developmental Psychopathology, 2nd ed. New York: Kluwer Academic; 2000. pp. 327-50.
20. Hassall E, et al. Omeprazole for maintenance therapy of erosive esophagitis in children. Gastroenterology 2000;118:A658.
21. Hassall E, Kerr W, El-Serag HB. Characteristics of children receiving proton pump inhibitors continuously for up to 11 years duration. J Pediatr 2007;150:262-7.
22. Canani RB, Cirillo P, Roggero P, et al. Therapy with gastric acidity inhibitors increases the risk of acute gastroenteritis and community-acquired pneumonia in children. Pediatrics 2006;117:e817-20.
23. Dial S, Delaney JA, Barkun AN, et al. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile- associated disease. JAMA 2005;294:2989-95.
24. Laheij RJ, Sturkenboom MC, Hassing RJ, et al. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA 2004;292:1955-60.
25. Valuck RJ, Ruscin JM. A case-control study on adverse effects: H2 blocker or proton pump inhibitor use and risk of vitamin B12 deficiency in older adults. J Clin Epidemiol 2004;57:422-8.
26. Yang YX, Lewis JD, Epstein S, et al. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006;296:2947-53.
27. Saiman L, Ludington E, Dawson JD, et al. Risk factors for Candida species colonization of neonatal intensive care unit patients. Pediatr Infect Dis J 2001;20:1119-24.
28. Guillet R, Stoll BJ, Cotton CM, et al. Association of H2 blocker therapy and higher incidence of necrotizing enterocolitis in very low birth weight infants. Pediatrics 2006;117:e137-42.
29. Orenstein SR, Gremse DA, Pantaleon CD, et al. Nizatidine for the treatment of pediatric gastroesophageal reflux symptoms: an open-label, multiple-dose, randomized, multicenter clinical trial in 210 children. Clin Ther 2005;27:472-83.